You are on page 1of 11

See

discussions, stats, and author profiles for this publication at: https://www.researchgate.net/publication/288690615

Update on the diagnosis and treatment of


hyperthyroidism

Article in Journal of clinical outcomes management: JCOM · June 2008

CITATIONS READS

2 21

1 author:

Elias S Siraj
Eastern Virginia Medical School
39 PUBLICATIONS 921 CITATIONS

SEE PROFILE

All content following this page was uploaded by Elias S Siraj on 01 August 2017.

The user has requested enhancement of the downloaded file.


Hyperthyroidism

Update on the Diagnosis and Treatment of


Hyperthyroidism
Case Study and Commentary, Elias S. Siraj, MD

CASE STUDY
Initial Presentation
CME jointly sponsored by
Wayne State University School of Medicine A 25-year-old woman presents to her physician
and JCOM
with symptoms of fatigue, headaches, and fluctuat-
ing weight. On examination, vital signs are within normal
This article has a companion CME exam that follows
range. Body mass index (BMI) is 28 kg/m2. Thyroid examina-
the article. To earn credit, read the article and com-
tion is unremarkable. A thyroid-stimulating hormone (TSH)
plete the CME evaluation on pages 306 and 307.
Estimated time to complete this activity is 1 hour. level is ordered and found to be low at 0.1 mIU/L (reference
Faculty disclosure information appears on page 304. range, 0.5–5.0 mIU/L). Free levorotatory thyroxine (T4) and
Release date: 15 June 2008; valid for credit through free triiodothyronine (T3) levels are subsequently checked
30 June 2009. and found to be normal.
Program Audience
Primary care physicians.
• How should the results of the patient’s thyroid function
Educational Needs Addressed tests be interpreted?
Signs and symptoms of hyperthyroidism are wide-
ranging and the frequency and severity of symp-
toms can vary, which makes diagnosis a chal- A patient with low TSH and normal T4 and T3 is consid-
lenge. Primary care physicians are often the first ered to have subclinical hyperthyroidism. Typically, these
to evaluate these patients. A detailed evaluation patients do not have clear signs and symptoms of hyper-
that includes questions about extent and duration thyroidism. The prevalence of subclinical hyperthyroidism
of symptoms, past medical history, family history, ranges from 0.7% to 12.4%. This variability is partly due to
physical examination (including thyroid examina- differences among studies in the definition of a low serum
tion), and appropriate laboratory tests can help
TSH value [1–4].
guide the treating physician to the etiology. Proper
The causes of subclinical hyperthyroidism are similar to
management depends on properly identifying the
cause of hyperthyroidism. Regular monitoring for those of overt hyperthyroidism (Table 1). The most common
changes in thyroid function is required, as progno- causes of subclinical hyperthyroidism are
sis can be adversely affected if a euthyroid state • Exogenous administration of levothyroxine for treating
is not maintained.
hypothyroidism. Among patients taking levothyroxine,
Educational Objectives as many as 25% may have low serum TSH values [5]
After participating in this CME activity, primary care • Autonomously functioning thyroid adenomas and
physicians should be able to multinodular goiters
1. Differentiate between etiologies of hyperthy-
roidism • Subacute thyroiditis
2. Describe management options for subclinical
hyperthyroidism • Less commonly, Graves’ disease
3. Outline the typical course of and management
strategies for subacute thyroiditis
4. Understand the approach to diagnosis and
management of Graves’ disease
5. Describe signs and symptoms of thyroid storm From the Department of Medicine, Section of Endocrinology, Diabetes and
Metabolism, Temple University School of Medicine, Philadelphia, PA.

298 JCOM June 2008 Vol. 15, No. 6 www.turner-white.com


case-Based review

Table 1. Common Causes of Hyperthyroidism


• What is the clinical significance of subclinical hyper-
Autoimmune thyroid disease
thyroidism?
Graves’ disease
Autonomous thyroid tissues
Toxic adenoma
The cardiovascular system and the skeletal system are the Toxic multinodular goiter
major organs affected by subclinical hyperthyroidism. Subacute thyroiditis
Subacute granulomatous thyroiditis (painful)
Skeletal System Subacute silent thyroiditis (painless)
Although some uncertainty remains, the majority of stud- Includes postpartum thyroiditis
ies in both exogenous and endogenous subclinical hyper- Exogenous thyroid hormone intake
thyroidism showed that a prolonged hyperthyroid state Excessive replacement dose
may lead to lower bone mineral density [6,7]. This may be Factitious hyperthyroidism
more pronounced in postmenopausal women. Whether de- Iodine-induced hyperthyroidism (including amiodarone)
creased bone mineral density translates into increased risk Thyroiditis
of fractures is unclear. Autonomous thyroid hormone production
Other rare causes
Cardiovascular hCG-mediated hyperthyroidism
As with overt hyperthyroidism, the frequency of atrial Struma ovarii
fibrillation is increased in patients with subclinical hyper- TSH-mediated (eg, Tsh-secreting pituitary adenoma)
thyroidism [8,9]. Increased occurrence of tachycardia and
ectopic beats may also be present. Possible induction of hCG = human chorionic gonadotropin; TSH = thyroid-stimulating
reentrant atrioventricular nodal tachycardia may occur in hormone.
predisposed patients. Increases in cardiac contractility and
left ventricular mass index as well as diastolic dysfunction TSH and bring the T4 and T3 levels toward low-
may be seen. Mortality studies are not conclusive as to normal while at the same time avoiding hypothyroid
whether risk of mortality is increased [10,11]. symptoms
• Radioactive iodine treatment is an option if radioac-
• Should subclinical hyperthyroidism be treated? tive iodine uptake and scan has shown autonomous
nodule or a low-grade Graves’ disease
• In patients where there is evidence of osteopenia or
The decision to treat subclinical hyperthyroidism depends osteoporosis, bisphosphonate treatment may have to
on several factors, including the age of the patient, degree be initiated to protect the bones
of abnormalities seen on thyroid function testing, and
presence or absence of risk factors for cardiovascular and Details regarding treatment options are described in more
skeletal complications. Observation is preferred if TSH level detail in subsequent sections.
is greater than 0.1 mIU/L and if there is a low risk of bone
or cardiac complications. Treatment should be considered Case Follow-up
if the patient is elderly, TSH level is less than 0.1 mIU/L, Given the asymptomatic nature of the patient’s sub-
or if there is evidence of or high risk for cardiac and bone clinical hyperthyroidism, a decision is made not to
complications [12]. In cases of exogenous subclinical hyper- start treatment. She is lost to follow-up for 3 years.
thyroidism, an attempt should be made to reduce the dose The patient then presents 2 months after delivering a
of the levothyroxine whenever possible. healthy baby complaining of dramatic weight loss, palpita-
If the decision is made to treat, treatment options include tions, and heat intolerance. On examination, heart rate is
the following: 110 bpm. She also has tremor, lid lag, and a slightly enlarged,
nontender thyroid. TSH is low at less than 0.002 mIU/L, and
• b Blockers may help to control some mild symptoms
T4 and T3 levels are high.
and also have protective effect on the heart
• Antithyroid drugs or thionamides can be used in
cases where b blockers are not considered to be ad- • What is the most likely diagnosis?
equate. The goal of treatment should be to normalize

www.turner-white.com Vol. 15, No. 6 June 2008 JCOM 299


Hyperthyroidism

Table 2. Clues to Causes of Hyperthyroidism A variant of subacute thyroiditis, sometimes called sub-
acute granulomatous thyroiditis, is characterized by neck
Feature Likely Disorder
pain and a tender, diffuse goiter in addition to the other
Diffuse goiter Graves’ disease characteristics. Postpartum thyroiditis is subacute thyroid-
Exophthalmos Graves’ disease itis that occurs in women within 1 year after parturition.
Pain and tenderness on the thyroid area Subacute thyroiditis The typical course of subacute thyroiditis is initially
Nodular goiter Toxic adenoma or characterized by hyperthyroidism followed by euthyroid-
toxic nodular goiter
ism, hypothyroidism, and ultimately restoration of normal
Recent intravenous contrast exposure Iodine-induced
thyroid function in most cases (Figure).
Patient taking amiodarone for a cardiac Amiodarone-induced
Subacute thyroiditis may have some pathologic simi-
condition
larities with Hashimoto’s disease, as many patients with
Hypothyroid patient taking levothyroxine Exogeneous
painless thyroiditis have high serum concentrations of an-
tithyroid microsomal (thyroid peroxidase) antibodies and
some develop overt chronic autoimmune thyroiditis several
As this patient is presenting in the immediate postpartum years later [14].
period, the physician should have a high degree of suspicion Treatment of patients with subacute thyroiditis is directed
for postpartum thyroiditis, whose presentation is similar to at relieving thyroid pain and tenderness and ameliorating
subacute thyroiditis. There are other clinical clues that can be symptoms of hyperthyroidism, if present. The few patients
helpful in identifying the cause of hyperthyroidism (Table 2). who have significant symptoms of hyperthyroidism, such
as palpitations, anxiety, or tremor, may benefit from treat-
ment with b blockers for few weeks. Some patients require
• Which tests may be helpful in the workup of the pa- no treatment because their symptoms are mild or subside by
tient with hyperthyroidism? the time they seek medical attention or when the diagnosis
is established. In some patients, anti-inflammatory therapy
with a nonsteroidal anti-inflammatory drug is indicated to
Laboratory tests may help in differentiating between the control pain; in patients with severe pain, steroids may be
causes of hyperthyroidism. Presence of TSH receptor anti- needed [16].
bodies, in particular thyroid-stimulating immunoglobulin,
indicates Graves’ disease. Very high thyroglobulin levels are Case Continued
consistent with subacute thyroiditis. The patient is prescribed b blockers for her post­
The radioactive iodine uptake and scan can be helpful in partum thyroiditis. She does not return to the office
determining the etiology of hyperthyroidism and can help for follow-up.
in directing treatment. Radioactive iodine uptake measures The patient returns for evaluation 5 years later. She
how much of the radioactivity given orally has been taken up re­ports that 5 years ago her thyroid “had gotten back to
by the thyroid over a period of time and is typically reported normal” after a few months on b blockers, but she has now
as a percentage. The scan complements the uptake and developed similar symptoms consisting of palpitations,
shows how the activity is distributed in the thyroid. Table 3 heat intolerance, and weight loss. On examination, she has
shows the results of radioactive iodine uptake and scan in the a diffuse goiter estimated at 2 to 3 times the normal size,
most commonly seen causes of hyperthyroidism. lid lag, and exophthalmos. TSH is suppressed at less than
0.002 mIU/L, and her T4 and T3 levels are high. TSH receptor
antibody level is elevated.
• What is subacute thyroiditis?

• What is the most likely diagnosis at this time?


Subacute thyroiditis is characterized by transient hyperthy- • What are other possible diagnoses?
roidism, occasionally followed by hypothyroidism, and then
• What are the next steps in evaluation?
recovery. Some patients have transient increases in serum
antithyroid antibody concentrations during the hypothy-
roid phase, probably caused by release of thyroid antigens The combination of clinical and biochemical hyperthyroid-
during the preceding period of inflammation [13]. After ism together with a diffuse goiter, exophthalmos, and positive
recovery, thyroid function is normal, as are ultrasonography TSH receptor antibody test suggests that Graves’ disease is
and thyroid biopsy [14,15]. the most likely diagnosis. Graves’ disease is the leading cause

300 JCOM June 2008 Vol. 15, No. 6 www.turner-white.com


case-Based review

Table 3. Radioactive Iodine Uptake and Scan in Various Forms of Hyperthyroidism

Disorder Uptake Scan Other Helpful Investigations


Graves’ disease Very high Diffuse activity in an enlarged gland Positive thyroid-stimulating hor-
mone receptor antibodies
Toxic adenoma Slightly high or normal Hot nodule + the rest of the gland
suppressed
Toxic nodular goiter Slightly high or normal Areas of intense activity interspersed
with areas of no/reduced activity
Subacute thyroiditis/postpartum Reduced or no uptake Faint diffuse activity or no activity at all High thyroglobulin
thyroiditis
Exogeneous levothyroxine Reduced or no uptake Faint diffuse activity or no activity at all Low thyroglobulin
Iodine-/amiodarone-induced Reduced or no uptake Faint diffuse activity or no activity at all High iodine in urine

of hyperthyroidism. It is an autoimmune disorder resulting Medications


from production of TSH receptor antibodies, which stimulate b Blockers. b Blockers ameliorate the symptoms of hyperthy-
thyroid gland growth and thyroid hormone synthesis and roidism that are caused by increased b-adrenergic tone [24].
release. Ophthalmopathy and pretibial myxedema are addi- These include palpitations, tachycardia, tremor, anxiety, and
tional autoimmune manifestations of Graves’ disease. heat intolerance. Thus, a b blocker should be started in most
Other diagnoses that should be considered include toxic patients as soon as the diagnosis of hyperthyroidism is made.
adenoma/toxic multinodular goiter, iodine-induced hyper-
thyroidism, and subacute thyroiditis. Toxic adenoma and Antithyroid drugs or thionamides. Antithyroid drugs or thi-
toxic multinodular goiter are the result of hyperplasia of thy- onamides are often started in patients with Graves’ hyper-
roid follicular cells whose functional capacity is independent thyroidism to attain a euthyroid state rapidly in preparation
of regulation by TSH. Activating somatic mutations of the for radioiodine therapy or thyroidectomy. However, patients
genes for the TSH receptor have been identified in both toxic who want to avoid or defer ablative therapy with radioiodine
adenomas and nodules of toxic multinodular goiters [17,18]. or surgery can continue thionamides for prolonged periods.
Although uncommon, iodine-induced hyperthyroidism can Although hyperthyroidism can almost always be controlled
develop after an iodine load, for example, after administra- as long as the drug is taken, there is only a modest hope
tion of contrast agents used for angiography or computed to- of attaining a permanent remission, which is about 20% to
mography or iodine-rich drugs such as amiodarone [19–21]. 30% within 1 to 2 years. It is also important to note that thi-
onamide therapy may have a negative effect on the efficacy
of subsequent radioactive iodine therapy. Methimazole
• How should this patient with Graves’ disease be and propylthiouracil (PTU) are the thionamides used to
treated? treat Graves’ hyperthyroidism. Methimazole is usually pre-
ferred because of its longer duration of action, allowing for
once-daily dosing, more rapid efficacy, and lower incidence
The therapeutic approach to Graves’ hyperthyroidism con- of side effects. PTU is preferred during pregnancy because
sists of rapid amelioration of symptoms with a b blocker and of the potential teratogenic effects of methimazole. Patients
measures aimed at decreasing thyroid hormone synthesis: should have their thyroid function assessed at 4- to 6-week
the administration of antithyroid drugs, radioactive iodine intervals until stabilized on maintenance antithyroid drug
ablation, or surgery [22]. In a randomized prospective trial therapy. Potential significant side effects of thionamides
comparing these 3 therapies, each was equally effective in include skin rash, agranulocytosis, and hepatotoxicity.
normalizing serum thyroid hormone concentrations within
6 weeks [23]. The risk of relapse was highest with antithy- Iodinated contrast agents and iodine. Patients with severe
roid drugs and lowest with surgery. hyperthyroidism or those who are allergic to antithyroid
In all types of treatment, initial monitoring should con- drugs may benefit from alternative medical therapies. The
sist of periodic clinical assessment and measurements of oral radiocontrast agents sodium ipodate and iopanoic acid
serum T4 and sometimes T3 levels. Serum TSH concentration are potent inhibitors of the peripheral conversion of T4 to T3.
may remain low for several weeks or even months after the They are not used as primary therapy because of possible in-
patient becomes euthyroid. duction of resistant hyperthyroidism. However, when given

www.turner-white.com Vol. 15, No. 6 June 2008 JCOM 301


Hyperthyroidism

600
500
400
300 40
200
100 20
TG, mg/mL

16 50 10
TSH, µU/mL

14 40 8
12 30 6
10 20 4
8 10 2 Normal
range
FTI

6 0 0
4
2

10 20 30 40 50 60 70 150

Days from onset of symptoms

Figure. Course of subacute thyroiditis. FTI = free thyroxine index; TG = thyroglobulin; TSH = thyroid-stimulating hormone.
(Reprinted with permission from DeGroot LJ, Larsen PR, Hennemann G. Acute and subacute thyroiditis. In: The thyroid and its
diseases. 6th ed. New York: Churchill Livingstone; 1996:705.)

in combination with antithyroid drugs, they can rapidly However, there are patients in whom it may be reason-
ameliorate severe hyperthyroidism and can also be used to able to delay radioiodine (or surgery), and therefore anti-
prepare a hyperthyroid patient for early surgery. thyroid drugs are the treatment of choice. Included in this
group are patients with mild hyperthyroidism and patients
Other medications. A number of other medications have with small goiters or with goiters that shrink during thio­
been used in the management of hyperthyroidism, includ- namide therapy. If radioiodine is chosen, the patient must be
ing the following: comfortable with the decision to ablate the thyroid, which in
most cases will result in permanent hypothyroidism.
• Glucocorticoids inhibit peripheral T4 to T3 conver-
Physicians and patients must also be aware that radioio-
sion and, in patients with Graves’ hyperthyroidism,
dine therapy may be associated with an increased risk of the
reduce thyroid hormone secretion. They have been
development or worsening of Graves’ ophthalmopathy [26].
used in patients with severe hyperthyroidism and
However, ophthalmopathy did not progress in a study of
thyroid storm
patients with minimal ophthalmopathy who were carefully
• Lithium blocks thyroid hormone release, but its use monitored to avoid hypothyroidism [27]. Some physicians
has been limited by its toxicity advocate the use of glucocorticoids at the time of radioiodine
• Cholestyramine, given in a dose of 4 g 4 times daily treatment to prevent such effects [28].
with methimazole, lowers serum T4 and T3 concen- Others suggest that radioactive iodine may not be the
trations more rapidly than methimazole alone treatment of choice in patients with significant ophthalmop-
athy. However, careful control of thyroid function before
Radioactive Iodine Ablation and after therapy and cessation of smoking by the patient
Ablation with radioiodine is widely used for the treatment may minimize ocular changes.
of Graves’ hyperthyroidism. It is the therapy of choice in the Radioactive iodine may be given as primary therapy to
United States, selected by approximately 70% of thyroid spe- patients with well-tolerated hyperthyroidism. In compari-
cialists [25]. It is considerably less popular in Europe (22%) son, patients who are not tolerating hyperthyroidism well,
and Japan (11%). are elderly, or have underlying heart disease are usually

302 JCOM June 2008 Vol. 15, No. 6 www.turner-white.com


case-Based review

Table 4. Comparison of Various Treatment Options for Graves’ Hyperthyroidism

Treatment Advantages Disadvantages


Thionamides Chance of permanent remission Minor side effects: rash, hives, arthralgias, fever, gastrointes-
Avoids permanent hypothyroidism tinal symptoms
Lower cost Low risk of agranulocytosis
Risk of fetal goiter and hypothyroidism if pregnant
Frequent visits to the physician
Radioactive iodine therapy Permanent resolution of hyperthyroidism Permanent hypothyroidism
Radiation precautions for several days after treatment; avoid
contact with young children and pregnant women
Surgery Rapid, permanent cure of hyperthyroidism Permanent hypothyroidism
Risk of hypoparathyroidism, recurrent laryngeal nerve dam-
age, and general anesthesia

Adapted with permission from Ross DS. Treatment of Graves’ hyperthyroidism. In: Rose BD, editor. UptoDate. Waltham (MA): UptoDate; 2008.
Copyright 2008, UptoDate, Inc. For more information, visit www.uptodate.com.

pretreated with an antithyroid drug to ameliorate hyperthy- in patients who have an obstructive goiter or a very large
roidism before radioactive iodine treatment. goiter, in pregnant women who are allergic to antithyroid
The goal of radioactive iodine therapy is destruction of drugs, and in patients who have allergies or poor compliance
the gland, with the early development of hypothyroidism. on antithyroid drugs but refuse radioactive iodine. Surgery
This eliminates the risk of recurrent hyperthyroidism. On the would also be indicated if there were a coexisting suspicious
other hand, some physicians prefer lower doses of radioactive or malignant thyroid nodule. However, most thyroid nodules
iodine with the aim of achieving a euthyroid state while low- associated with Graves’ disease are benign, in which case
ering the risk of early hypothyroidism [29]. However, many of surgery would not be recommended [31]. Patients who want
these patients have persistent subclinical or overt hyperthy- rapid restoration of euthyroidism, are concerned about radio-
roidism. Furthermore, there is a risk of both recurrent overt activity, or have had an adverse effect with thionamide drugs
hyperthyroidism and insidious-onset late hypothyroidism. may also prefer surgery.
Approximately 20% of patients fail the first radioactive Thyroidectomy during pregnancy may be necessary in
iodine treatment and require a subsequent dose. These pa- women who cannot tolerate antithyroid drugs because of
tients usually have more severe hyperthyroidism or larger allergy or agranulocytosis. The indications for surgery are
goiters. similar to those in nonpregnant women and men. Table 4
summarizes and compares treatment options for Graves’
Radioactive iodine therapy in toxic adenoma or toxic multi- hyperthyroidism.
nodular goiter. Depending upon patient preference, either ra-
dioactive iodine therapy or surgery is the treatment of choice Case Continued
for toxic adenoma or toxic multinodular goiter. An occasional The patient is started on methimazole, and her hy­
patient can be managed, if preferred or necessary for other perthyroidism is well controlled with this treatment.
reasons, with antithyroid drugs. One year later she presents to the emergency department
Radioactive iodine therapy is less controversial in pa- with dyspnea, palpitations, fever, tremor, and agitation.
tients with a toxic adenoma or toxic multinodular goiter. Thyroid function tests show results consistent with severe
Areas of focal autonomy take up radioiodine well, while hyperthyroidism. She also has atrial fibrillation with rapid
uptake is limited in adjacent and contralateral thyroid tis- ventricular response. Upon questioning, the patient reports
sue that has been suppressed by the hyperthyroid state. As that she has not taken her thyroid medication for a while,
a result, radioiodine tends to destroy only the autonomous since she ran out.
areas, and most patients remain euthyroid after radioiodine
administration [30].
• What does the patient’s presentation suggest?
Surgery
With the availability of other options, surgery is a less popular
therapy for Graves’ hyperthyroidism. It is primarily indicated Patients with severe and life-threatening thyrotoxicosis

www.turner-white.com Vol. 15, No. 6 June 2008 JCOM 303


Hyperthyroidism

typically have an exaggeration of the usual symptoms of may not be her best long-term therapy option. Definitive
hyperthyroidism. This type of presentation is usually called therapy with radioactive iodine treatment may be a better
thyroid storm. choice for this patient.
Cardiovascular symptoms include severe tachycardia
along with congestive heart failure in many patients. Hyper­ Corresponding author: Elias S. Siraj, MD, Associate Professor of Medi-
pyrexia to 104ºF to 106ºF is common. Agitation, delirium, cine, Temple University Hospital, 3322 N. Broad St., Philadelphia, PA
psychosis, stupor, or coma are common and are considered 19140.
by many to be essential to the diagnosis. Severe nausea,
vomiting, or diarrhea, and hepatic failure with jaundice can Financial disclosures: None.
also occur.
Although thyroid storm can develop in patients with References
long-standing untreated hyperthyroidism, it is more often 1. Sawin CT, Geller A, Kaplan MM, et al. Low serum thyrotropin
precipitated by an acute event such as thyroid or nonthyroi- (thyroid-stimulating hormone) in older patients without hy-
perthyroidism. Arch Intern Med 1991;151:165–8.
dal surgery, trauma, infection, or an acute iodine load. The
2. Parle JV, Franklyn JA, Cross KW, et al. Prevalence and follow-
advent of appropriate preoperative preparation of patients up of abnormal thyrotrophin (TSH) concentrations in the
undergoing thyroidectomy for hyperthyroidism has led to a elderly in the United Kingdom. Clin Endocrinol (Oxf) 1991;34:
dramatic reduction in the prevalence of surgically induced 77–83.
thyroid storm. 3. Hollowell JG, Staehling NW, Flanders WD, et al. Serum TSH,
T(4) and thyroid antibodies in the United States popula-
tion (1988 to 1994): National Health and Nutrition Survey
(NHANES III). J Clin Endocrinol Metab 2002;87:489–99.
• How is thyroid storm managed?
4. Belin RM, Astor BC, Powe NR, Ladenson PW. Smoke exposure
is associated with a lower prevalence of serum thyroid autoan-
The therapeutic options for thyroid storm are the same as for tibodies and thyrotropin concentration elevation and a higher
prevalence of mild thyrotropin concentration suppression in
uncomplicated hyperthyroidism, except that the drugs are
the third National Health and Nutrition Examination Survey
given in higher doses and more frequently. In addition, full (NHANES III). J Clin Endocrinol Metab 2004;89:6077–86.
supportive therapy of the patient in an intensive care unit is 5. De Whalley P. Do abnormal thyroid-stimulating hormone level
essential, since the mortality rate of thyroid storm is high. values results in treatment changes? A study of patients on
Supportive therapy should address various issues. Many thyroxine in one general practice. Br J Gen Pract 1995;45:93–5.
patients require a substantial amount of fluid. Others may 6. Foldes J, Tarjan G, Szathmari M, et al. Bone mineral density in
require diuresis because of congestive heart failure whereby patients with endogenous subclinical hyperthyroidism: is this
digoxin requirements may be quite high. Infections need to thyroid status a risk factor for osteoporosis? Clin Endocrinol
be identified and treated. Hyperpyrexia should be aggres- 1993;39:521–7.
sively corrected. 7. Faber J, Galloe AM. Changes in bone mass during prolonged
The therapeutic regimen typically consists of multiple subclinical hyperthyroidism due to L-thyroxine treatment: a
meta-analysis. Eur J Endocrinol 1994;130:350–6.
medications, each of which has a different mechanism of
8. Sawin CT, Geller A, Wolf PA, et al. Low serum thyrotropin
action. b Blockers are used to control symptoms induced concentrations as a risk factor for atrial fibrillation in older
by increased adrenergic tone. A thionamide, such as meth­ persons. N Engl J Med 1994;331:1249–52.
imazole, is needed to block new hormone synthesis. An 9. Auer J, Scheibne P, Mische T, et al. Subclinical hyperthyroid-
iodinated radiocontrast agent can be used to inhibit the ism as a risk factor for atrial fibrillation. Am Heart J 2001;
peripheral conversion of T4 to T3. An iodine solution will 142:838–42.
help block the release of thyroid hormones. Glucocorticoids 10. Cappola AR, Fried LP, Arnold AM, et al. Thyroid status, car-
will help reduce T4-to-T3 conversion and possibly treat the diovascular risk, and mortality in older adults. JAMA 2006;295:
autoimmune process in Graves’ disease. 1033–41.
11. Iervasi G, Molinaro S, Landi P, et al. Association between
increased mortality and mild thyroid dysfunction in cardiac
patients. Arch Intern Med 2007;167:1526–32.
• What should be recommended for long-term manage- 12. Surks MI, Ortiz E, Daniels GH, et al. Subclinical thyroid
ment of this patient’s Graves’ disease? disease: scientific review and guidelines for diagnosis and
management. JAMA 2004;291:228–38.
13. Volpe R, Row VV, Ezrin C. Circulating viral and thyroid anti-
This patient has developed atrial fibrillation and admits to bodies in subacute thyroiditis. J Clin Endocrinol Metab 1967;
not adhering to her medication regimen. Antithyroid drugs 27:1275–84.

304 JCOM June 2008 Vol. 15, No. 6 www.turner-white.com


case-Based review

14. Nikolai TF, Coombs GJ, McKenzie AK. Lymphocytic thy- ism: treatment with antithyroid drugs, surgery, or radioiodine
roiditis with spontaneously resolving hyperthyroidism and —a prospective, randomized study. J Clin Endocrinol Metab
subacute thyroiditis: long-term follow-up. Arch Intern Med 1996;81:2986–93.
1981;141:1455–8. 24. Geffner DL, Hershman JM. Beta-adrenergic blockade for the
15. Brander A. Ultrasound appearances in de Quervain’s sub- treatment of hyperthyroidism. Am J Med 1992;93:61–8.
acute thyroiditis with long-term follow-up. J Intern Med 1992; 25. Wartofsky L, Glinoer D, Solomon B, et al. Differences and
232:321–5. similarities in he diagnosis and treatment of Graves’ disease in
16. Yamamoto M, Saito S, Sakurada T, et al. Effect of prednisolone Europe, Japan, and the United States. Thyroid 1991;1:129–35.
and salicylate on serum thyroglobulin level in patients with 26. Tallstedt L, Lundell G, Torring O, et al. Occurrence of ophthal-
subacute thyroiditis. Clin Endocrinol 1987;27:339–44. mopathy after treatment for Graves’ hyperthyroidism. The
17. Duprez L, Hermans J, Van Sande J, et al. Two autonomous Thyroid Study Group. N Engl J Med 1992;326:1733–8.
nodules of a patient with multinodular goiter harbor different 27. Perros P, Kendall-Taylor P, Neoh C, et al. A prospective study
activating mutations of the thyrotropin receptor gene. J Clin of the effects of radioiodine therapy for hyperthyroidism in
Endocrinol Metab 1997;82:306–8. patients with minimally active graves’ ophthalmopathy. J Clin
18. Holzapfe HP, Fuhrer D, Wonerow P, et al. Identification of con- Endocrinol Metab 2005;90:5321–3.
stitutively activating somatic thyrotropin receptor mutations 28. Wartofsky L. Therapeutic controversies. Summation, com-
in a subset of toxic multinodular goiters. J Clin Endocrinol mentary, and overview: concerns over aggravation of Graves’
Metab 1997;82:4229–33. ophthalmopathy by radioactive iodine treatment and the use
19. Conn JJ, Sebastian MJ, Deam D, et al. A prospective study of retrobulbar radiation therapy. J Clin Endocrinol Metab 1995;
of the effect of nonionic contrast media on thyroid function. 80:347–9.
Thyroid 1996;6:107–10. 29. Goolden AW, Stewart JS. Long-term results from graded low
20. Martin FI, Tress BW, Colman PG, Dream DR. Iodine-induced dose radioiodine therapy for thyrotoxicosis. Clin Endocrinol
hyperthyroidism due to nonionic contrast radiography in the 1986;24:217–22.
elderly. Am J Med 1993;95:78–82. 30. Ross DS, Ridgway EC, Daniels GH. Successful treatment of
21. Harjai KJ, Licata AA. Effects of amiodarone on thyroid func- solitary toxic thyroid nodules with relatively low-dose iodine-
tion. Ann Intern Med 1997;126:63–73. 131, with low prevalence of hypothyroidism. Ann Intern Med
22. Singer PA, Cooper DS, Levy EG, et al. Treatment guidelines for 1984;101:488–90.
patients with hyperthyroidism and hypothyroidism. JAMA 31. Cantalamessa L, Baldini M, Orsatti A, et al. Thyroid nodules in
1995;273:808–12. Graves’ disease and the risk of thyroid carcinoma. Arch Intern
23. Torring O, Tallsted, L, Wallin G, et al. Graves’ hyperthyroid- Med 1999;159:1705–8.
Copyright 2008 by Turner White Communications Inc., Wayne, PA. All rights reserved.

www.turner-white.com Vol. 15, No. 6 June 2008 JCOM 305


JCOM
CME

CME EVALUATION: Update on the Diagnosis and Treatment of Hyperthyroidism

DIRECTIONS: Each of the questions below is followed by several possible answers. Select the ONE lettered answer
that is BEST in each case and circle the corresponding letter on the answer sheet.

1. In deciding whether to treat subclinical hyperthyroidism, 4. Thyroidectomy in hyperthyroidism is indicated in all of


all of the following factors are important EXCEPT the following cases EXCEPT
A. Presence of cardiac complications A. Patients with thyroid storm
B. Presence of osteopenia/osteoporosis B. Patients with a coexisting suspicious or malignant
C. Presence of thyroid nodules nodule
D. Age C. Patients with obstructive goiter
E. Thyroid-stimulating hormone level D. Pregnant women allergic to antithyroid drugs

2. All of the following could be manifestations of subacute 5. In regard to thyroid storm, all of the following are true
thyroiditis EXCEPT EXCEPT
A. Hyperthyroidism A. Patients may present with congestive heart failure
B. Hypothyroidism B. Usually there is an identifiable precipitating factor
C. Pretibial myxedema C. Blocking the conversion of T4 to T3 is an important
D. Thyroid pain and tenderness part of the treatment
D. The incidence of surgically induced thyroid storm
3. All of the following regarding radioactive iodine therapy has increased recently
in Graves’ disease are true EXCEPT
A. It is the most widely used therapy in the United
States
B. It can lead to agranulocytosis
C. It may be associated with worsening ophthalmopa-
thy
D. It results in permanent hypothyroidism in most
patients

306 JCOM June 2008 Vol. 15, No. 6 www.turner-white.com


JCOM
CME

EVALUATION FORM: Update on the Diagnosis and Treatment of Hyperthyroidism

Participants may earn 1 credit by reading the article named above Please print clearly:
and correctly answering at least 70% of the accompanying test
questions. A certificate of credit and the correct answers will be Name:__________________________________________________
mailed within 6 weeks of receipt of this page to those who success-
MD/DO/Other:_________________________________________
fully complete the test.
Address:_ ______________________________________________
Circle your answer to the CME questions below:
1. A B C D E _______________________________________________________

2. A B C D City:___________________________________________________
3. A B C D State:______________________________  Zip:______________
4. A B C D
Phone:_ ________________________________________________
5. A B C D
Fax:____________________________________________________
Please answer the following questions:
E-mail:_________________________________________________
1. How would you rate this educational activity overall?
__ Excellent __ Good __ Fair __ Poor Are you a health care professional licensed to practice in the US/
Canada who can use Category 1 AMA PRA CME credit to
2. This article was fair, balanced, free of commercial bias, and fully fulfill educational requirements? ____ Yes ____ No
supported by scientific evidence.
__ Yes __ No Physicians are required to report the actual amount of time spent
on the activity, up to the maximum designated 1 hour. The actual
3. Please rate the clarity of the material presented in the article. time spent reading this article and completing the test was
____________________.
__ Very clear __ Somewhat clear __ Not at all clear

4. How helpful to your clinical practice was this article?


__ Very helpful __ Somewhat helpful __ Not at all helpful
Please mail or fax this sheet to:

5. What changes will you make in your practice as a result of Wayne State University, Division of CME
101 E. Alexandrine, Lower Level
reading this article?
Detroit, MI 48201
____________________________________________________
____________________________________________________ FAX: 313-577-7554
____________________________________________________
____________________________________________________
____________________________________________________
____________________________________________________ This activity has been planned and implemented in ac-
cordance with the Essential Areas and Policies of the
Accredi­tation Coun­cil for Continuing Medical Education
6. What topics would you like to see presented in the future?
(ACCME) through the joint sponsorship of Wayne State
____________________________________________________
University School of Medicine and the Journal of Clinical
____________________________________________________ Outcomes Manage­ment. Wayne State Uni­versity School of
____________________________________________________ Medicine is accredited by the ACCME to provide continu-
____________________________________________________ ing medical education for physicians.
____________________________________________________ Wayne State University School of Medicine designates this
____________________________________________________ educational activity for a maximum of 1 AMA PRA Category
1 credits. Physicians should only claim credit commensurate
with the extent of their participation in the activity.
Release date: 15 June 2008
Expiration date: 30 June 2009

www.turner-white.com Vol. 15, No. 6 June 2008 JCOM 307

View publication stats

You might also like